Table 1. Demographic characteristics and TPO results of patients in different groups.
| - | Nonpregnant healthy control n = 35 | Healthy pregnancy n = 32 | GT n = 31 | ITP in pregnancy n = 35 | Age-matched nonpregnant ITP n = 32 |
|---|---|---|---|---|---|
| Age (yr), median, (range) |
29, (22-39) | 27, (21-39) | 28, (18-36) | 27, (21-38) | 30, (18-45) |
| Gestational age (wk), median, (range) |
NA | 23, (6-41) | 36, (29-41) | 30, (8-39) | NA |
| Platelet count (×109/L) median, (range) |
256, (182-297) | 232, (190-277) | 81, (53-99) | 18, (4-43) | 21, (1-58) |
| TPO level (pg/mL) mean ± SD |
37 ± 15 | 65 ± 22 | 187 ± 64 | 1283 ± 646 | 88 ± 41 |
| Newly diagnosed or persistent ITP, n (%) | NA | NA | NA | 29 (82.9%) | 23 (71.9%) |
| Chronic ITP, n (%) | NA | NA | NA | 6 (17.1%) | 9 (28.1%) |
| Current ITP therapy, n (%) |
|||||
| Any | NA | NA | NA | 6 (17.1%) | 8 (25.0 %) |
| Corticosteroid | NA | NA | NA | 5 (14.3%) | 6 (18.8%) |
| IVIg | NA | NA | NA | 2 (5.7%) | 3 (9.4%) |
| Rituximab | NA | NA | NA | 0 (0.0%) | 1 (3.1%) |
| Other | NA | NA | NA | 0 (0.0%) | 2 (6.3%) |
| No therapy | NA | NA | NA | 29 (82.9%) | 24 (75.0%) |
| Platelet count after delivery (×109/L), n | NA | NA | 22 | 20 | NA |
| median, (range) | NA | NA | 241, (170-274) |
74, (37-167) |
NA |
| TPO level after delivery (pg/mL), n | NA | NA | 0 | 8 | NA |
| mean ± SD | NA | NA | NA | 95 ± 32 | NA |